In the BioHarmony Drug Report Database

"Preview" Icon

Cinacalcet

Sensipar, Mimpara (cinacalcet) is a small molecule pharmaceutical. Cinacalcet was first approved as Sensipar on 2004-03-08. It is used to treat parathyroid neoplasms, primary hyperparathyroidism, and secondary hyperparathyroidism in the USA. It has been approved in Europe to treat hypercalcemia, hyperparathyroidism, parathyroid neoplasms, and secondary hyperparathyroidism. The pharmaceutical is active against extracellular calcium-sensing receptor. In addition, it is known to target metabotropic glutamate receptor 5. Sensipar’s patent is valid until 2026-09-22 (FDA).

 

Trade Name

 

Mimpara
 

Common Name

 

cinacalcet
 

ChEMBL ID

 

CHEMBL1201284
 

Indication

 

hypercalcemia, hyperparathyroidism, parathyroid neoplasms, primary hyperparathyroidism, secondary hyperparathyroidism
 

Drug Class

 

Calcium receptor agonists

Image (chem structure or protein)

Cinacalcet structure rendering